Pharmaceutical Drugs

Product Details:

Ustekinumab, sold under the brand name Stelara is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23.

Additional Information:

• Production Capacity: 20
• Delivery Time: read

Product Details:

Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.

Product Details:

Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. 

We have Pirfinex from Cipla
Fiboresp From Glenmark
Pirfisun from Sunrise

Product Details:

We are a renowned provider of the Tygacil 50 mg is widely used for treating complicated intraabdominal infections and complicated skin and skin structure infections. Having being available since 1990’s in the medical industry, in recent years this drug has been limited by widespread resistance to these agents. We ensure that this drug is manufactured under stringent supervision which involves a detailed quality check for maintaining the desired quality.

 

Features:

 

• High end advanced medical property.
• Reliable drug.
• Minimum side effects.

Product Details:

PTH 30 mg Tablet is a calcimimetic agent, a drug that mimics or copies the actions of calcium on the tissues. It is used to treat secondary hyperparathyroidism as well as hypercalcemia (high blood calcium levels). This medicine is not recommended for use in patients less than 18 years of age.

Product Details:

Onglyza contains saxagliptin 5 mg

Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic of the dipeptidyl peptidase-4 inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.

Other Information

• Minimum Order Quantity: 1 pack